PR

Precision medicine

Cambridge, GB · 2 known investors

phoremost.com ↗

PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.

Investors · 2

AS

Astellas Venture Management LLCSouth San Francisco · $200K – $5M

CA

Cambridge Angels groupCambridge · $195K – $1.9M